Clinical Trial Update: Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer [NA]

View source ↗

Summary

Clinical trial update on combining anlotinib hydrochloride with EGFR TKIs for advanced non-small cell lung cancer; phase and status are not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Non-Small-Cell Lung | NA | Status: UNKNOWN